 |
 |
If you’d like to join me in letting Carrie Scott, Global Head, Corporate Responsibility Communications and Reporting, know what you think of Novartis cost of $10,000 a month for nilotinib, a cancer drug that has dramatically helped late stage Parkinson patients in a Phase 1 trial. her email is: [log in to unmask] I understand that the drugs developer Dr. Brian Druker received a taxpayer funded NIH grant to do the research. Novartis mission statement is patient “caring and curing”. How is this possible at $125,000 year for a drug patients can’t afford ? If you do decide to express yourself, please just cc me with your comments. Feel free to use anything I have written or email me if you have questions. Trials are planned for Alzheimers too. How awful if there is hope,, but only for the rich. Ray Rayilyn Brown Past Director AZNPF Arizona Chapter National Parkinson Foundation ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn